Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCB:CGXP), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).

“The introduction of EpiCeram® is a terrific addition to our current line of products.”

The Agreement grants BioPro exclusivity in the Territories for the distribution and marketing of EpiCeram® while Ceragenix will be responsible for the manufacturing and supply of the product. BioPro is also responsible for obtaining regulatory clearance to market EpiCeram® in the Territories. Financial terms were not disclosed.

Steven Porter Chairman and Chief Executive Officer of Ceragenix said, "We are very pleased to expand our Asian footprint for EpiCeram® by partnering with BioPro. We are very impressed with their capabilities and we look forward to working with them. ”

"We are delighted to enter into this agreement for the Distribution and Supply of Ceragenix’s EpiCeram® for treating atopic dermatitis and other dry skin conditions. There is an unmet medical need in that use of EpiCeram® has been shown to be very effective in comparison with a number of steroidal based products while offering an improved margin of clinical safety” said Peter Huang, Chairman and CEO of BioPro Pharmaceutical, Inc. "The introduction of EpiCeram® is a terrific addition to our current line of products.